Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down - What's Next?

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report)'s stock price gapped down before the market opened on Monday . The stock had previously closed at $11.45, but opened at $10.70. Dyne Therapeutics shares last traded at $10.29, with a volume of 114,542 shares trading hands.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on DYN. Robert W. Baird started coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They issued an "outperform" rating and a $46.00 target price for the company. Piper Sandler lowered their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Guggenheim restated a "buy" rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. HC Wainwright reiterated a "buy" rating and set a $46.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 17th. Finally, JPMorgan Chase & Co. cut their price objective on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a research report on Friday, March 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $47.46.

Dyne Therapeutics Stock Performance

The company has a market cap of $936.64 million, a price-to-earnings ratio of -2.33 and a beta of 1.11. The firm's 50 day simple moving average is $12.92 and its 200-day simple moving average is $22.87.

Remove Ads

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.04. As a group, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares of the company's stock, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 6,237 shares of company stock worth $77,760 in the last 90 days. Insiders own 20.77% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Quantbot Technologies LP purchased a new stake in shares of Dyne Therapeutics in the 3rd quarter valued at approximately $34,000. Point72 DIFC Ltd acquired a new stake in Dyne Therapeutics in the 3rd quarter valued at approximately $36,000. GF Fund Management CO. LTD. purchased a new stake in Dyne Therapeutics in the fourth quarter valued at approximately $50,000. KBC Group NV lifted its stake in Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company's stock worth $74,000 after purchasing an additional 978 shares in the last quarter. Finally, Summit Investment Advisors Inc. lifted its stake in Dyne Therapeutics by 9.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock worth $203,000 after purchasing an additional 721 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.